127. Frontotemporal lobar degeneration Clinical trials / Disease details
Clinical trials : 90 / Drugs : 87 - (DrugBank : 30) / Drug target genes : 39 - Drug target pathways : 88
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04680130 (ClinicalTrials.gov) | November 1, 2020 | 3/11/2020 | Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders | Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders | PSP;CBD;PCA;LPA;Semantic Dementia;Semantic Aphasia;Behavioral Variant of Frontotemporal Dementia;FTD;PPA;Apraxia of Speech | Drug: C-11 PiB;Drug: AV1451 Tau | Mayo Clinic | NULL | Enrolling by invitation | 21 Years | N/A | All | 500 | United States |